![female scientist with vials using a microscope](/sites/default/files/styles/445x610/public/media/images/asian_female_scientist_profile_0.jpg.webp?itok=OwwtMkUs)
Tumor mutation burden (TMB) and colorectal cancer.
![female scientist with vials using a microscope](/sites/default/files/styles/445x610/public/media/images/asian_female_scientist_profile_0.jpg.webp?itok=OwwtMkUs)
![damaged DNA](/sites/default/files/styles/fifty_fifty/public/media/images/dna_mutation.jpg.webp?itok=PFGPr76e)
What is tumor mutation burden (TMB)?
Tumor mutation burden (TMB) is a measure of the number of mutations carried by tumor cells. Tumors with many mutations have a high mutation burden (high TMB).
Many tumors with a high TMB (equal to or greater than 10) also have the biomarker MSI-H.
In MSI-H tumors, the somatic mutation occurs in one of the DNA mismatch repair genes that also results in MSI-H. These mutations can be passed along to new tumor cells during cell division. A small percentage of tumors with TMB also have the biomarker MSS.
![female healthcare provider giving a consultation](/sites/default/files/styles/fifty_fifty/public/media/images/black_provider_with_afro.jpg.webp?itok=umhWWLMf)
What happens if I have a high TMB?
Knowing the TMB score of a tumor may help predict how well it will respond to immunotherapies.
This can help you and your doctor find the right treatment plan for you.
Other biomarkers
UGT1A1 BiomarkerTop resources
![A sign at the BMS headquarters](/sites/default/files/styles/450x250/public/media/images/bms-sign-1920.png.webp?itok=qtRzhXHJ)
Krazati approved for previously treated KRASG12C colorectal cancer
The treatment option is for patients with KRASG12C-mutated locally advanced or metastatic colorectal cancer (CRC) who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.
![Christy Williams, a mom and colorectal cancer survivor, plays a table-top game with her family.](/sites/default/files/styles/450x250/public/media/images/christy-3.png.webp?itok=DxDhUqH-)
Christy Williams: Biomarker testing leads to successful treatment
Statistics suggested that Christy’s odds of survival were grim, so she leaned into her faith and kept a positive outlook. She tried to control what she could. And, critically, she received biomarker testing.
![Michelle Cappel: Biomarker testing extends life](/sites/default/files/styles/450x250/public/media/images/article/michelle-c-web.png.webp?itok=fV1oBKbJ)
Michelle Cappel: Biomarker testing extends life
Michelle Cappel owes a lot to colorectal cancer biomarker testing — seven years of life and counting.